Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03341156
Other study ID # STUDY19020099
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date July 11, 2018
Est. completion date December 1, 2024

Study information

Verified date January 2024
Source University of Pittsburgh
Contact Amy Monroe
Phone 412-623-6382
Email Monroeal@upmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is comparing the use of Kcentra vs. standard transfusion in patients undergoing heart transplantation surgery. Half of the patients will receive Kcentra, while the other half will receive fresh frozen plasma.


Description:

This study will be a randomized (1:1; PCC vs. plasma), open-label trial of hemostatic therapies during heart transplantation. The goal is to enroll 60 patients. Informed consent will be obtained from patients meeting the inclusion and exclusion criteria before the initiation of any study specific procedures. Eligible patients will be randomized to receive either PCC or plasma transfusion. The efficacy of interventions will be evaluated after 30 minutes of protamine administration. After the heart transplantation, thrombocytopenia and/or hypofibrinogenemia may worsen bleeding associated with vitamin K dependent factor deficiencies. Transfusion of platelets and/or cryoprecipitate is permitted if abnormal laboratory values are observed during the rewarming phase of CPB; platelet count <100 x 103/µl, and fibrinogen <200 mg/dl, respectively. Laboratory tests (hematocrit, platelet count, PT, PTT, POC-PT, coagulation factor and inhibitor levels (e.g., factor II, antithrombin), thromboelastometry or thromboelastography, endogenous thrombin generation) will also be obtained at baseline, twice during surgery and at 12-24 hours after surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 1, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be willing and able to provide written informed consent. - Be at least 18 years of age. - Patients with or without ventricular assist device (VAD) undergoing heart transplantation - Patients who have been on warfarin for at least 72 hours before cardiopulmonary bypass procedures for heart transplantation. - International normalization ration (INR) greater than or equal to 1.5 - Body temperature greater than 35.0 degrees Celsius. - Blood pH greater than 7.2 - Hemoglobin greater than 7.0 mg/dL. Exclusion Criteria: - Treatment with clopidogrel, prasugrel, or ticagrelor within 5 days prior to study surgery. - Known or suspected thrombophilia such as factor V Leiden, hereditary antithrombin III deficiency, heparin-induced thrombocytopenia, disseminated intravascular coagulation. - Ischemic or thromboembolic events within 6 weeks of study surgery. - Known allergy/anaphylaxis to prothrombin complex concentrate or albumin. - Any indication that a potential subject did not comprehend the study restrictions, procedures. or consequences therein an informed consent cannot be convincingly given. - Patients on respiratory support including extracorporeal membrane oxygenation (ECMO) . - Life expectancy less than 48 hours. - Excluded at the discretion of the surgeon based upon surgical safety precautions

Study Design


Intervention

Drug:
Kcentra
Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
Frozen Plasma Product, Human
If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.

Locations

Country Name City State
United States University of Maryland Baltimore Maryland
United States Upmc Presbyterian Montefiore Hospital Pittsburgh Pennsylvania
United States UPMC Presbyterian Shadyside Pittsburgh Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
Kathirvel Subramaniam CSL Behring, University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

References & Publications (17)

Balsam LB, Timek TA, Pelletier MP. Factor eight inhibitor bypassing activity (FEIBA) for refractory bleeding in cardiac surgery: review of clinical outcomes. J Card Surg. 2008 Nov-Dec;23(6):614-21. doi: 10.1111/j.1540-8191.2008.00686.x. Epub 2008 Sep 10. — View Citation

Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010 Nov;113(5):1205-19. doi: 10.1097/ALN.0b013e3181f22b5a. — View Citation

Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010 Oct;99(3):251-60. doi: 10.1111/j.1423-0410.2010.01339.x. — View Citation

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015 May 23;385(9982):2077-87. doi: 10.1016/S0140-6736(14)61685-8. Epub 2015 Feb 27. — View Citation

Kantorovich A, Fink JM, Militello MA, Wanek MR, Smedira NG, Soltesz EG, Moazami N. Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant. Ann Pharmacother. 2015 Aug;49(8):876-82. doi: 10.1177/1060028015585344. Epub 2015 May 18. — View Citation

Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, Crowther MA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg. 2010 Jun 1;110(6):1533-40. doi: 10.1213/ANE.0b013e3181db7991. Epub 2010 Apr 30. — View Citation

Marshall AL, Levine M, Howell ML, Chang Y, Riklin E, Parry BA, Callahan RT, Okechukwu I, Ayres AM, Nahed BV, Goldstein JN. Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal. J Thromb Haemost. 2016 Feb;14(2):324-30. doi: 10.1111/jth.13212. Epub 2016 Feb 2. — View Citation

Mathias T, Puca KE, Downey F, Boyle AJ: Use of Vitamin K and Prothrombin Complex Concentrate as Warfarin Reversal Prior to Heart Transplant. Journal of Heart and Lung Transplantation 2012; 31: S154

Ortmann E, Besser MW, Sharples LD, Gerrard C, Berman M, Jenkins DP, Klein AA. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg. 2015 Jul;121(1):26-33. doi: 10.1213/ANE.0000000000000689. — View Citation

Rao VK, Lobato RL, Bartlett B, Klanjac M, Mora-Mangano CT, Soran PD, Oakes DA, Hill CC, van der Starre PJ. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery. J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1221-6. doi: 10.1053/j.jvca.2014.04.015. — View Citation

Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 Sep 10;128(11):1234-43. doi: 10.1161/CIRCULATIONAHA.113.002283. Epub 2013 Aug 9. — View Citation

Scott E, Puca K, Heraly J, Gottschall J, Friedman K. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6 degrees C storage. Transfusion. 2009 Aug;49(8):1584-91. doi: 10.1111/j.1537-2995.2009.02198.x. — View Citation

Song HK, Tibayan FA, Kahl EA, Sera VA, Slater MS, Deloughery TG, Scanlan MM. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg. 2014 Mar;147(3):1036-40. doi: 10.1016/j.jtcvs.2013.11.020. Epub 2013 Dec 22. — View Citation

Subramaniam K. Early graft failure after heart transplantation: prevention and treatment. Int Anesthesiol Clin. 2012 Summer;50(3):202-27. doi: 10.1097/AIA.0b013e3182603ead. No abstract available. — View Citation

Tanaka KA, Mazzeffi MA, Grube M, Ogawa S, Chen EP. Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion. 2013 Apr;53(4):920-1. doi: 10.1111/trf.12110. No abstract available. — View Citation

Tanaka KA, Mazzeffi MA, Strauss ER, Szlam F, Guzzetta NA. Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery. J Anesth. 2016 Jun;30(3):369-76. doi: 10.1007/s00540-015-2128-3. Epub 2016 Jan 9. — View Citation

Tholpady A, Monson J, Radovancevic R, Klein K, Bracey A. Analysis of prolonged storage on coagulation Factor (F)V, FVII, and FVIII in thawed plasma: is it time to extend the expiration date beyond 5 days? Transfusion. 2013 Mar;53(3):645-50. doi: 10.1111/j.1537-2995.2012.03786.x. Epub 2012 Jul 15. — View Citation

* Note: There are 17 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Direct Cost Benefit Acquisition costs for test agents and blood bank related charges (thawing, etc.) From infusion until 30 days post heart transplant
Other Total surgical time Total time of surgical duration will be measured in the corresponding time frame From anesthesia start time until anesthesia stop time
Other Time to hospital discharge Time until discharge from the hospital post study intervention will be measured From patient out of room time to hospital discharge (or 30 days post heart transplant, whichever comes first)
Other Time to Intensive Care Unit (ICU) discharge Time until discharge from the ICU post study intervention will be measured From patient out of room time to ICU discharge (or 30 days post heart transplant, whichever comes first)
Other Indirect Cost Benefits Extra costs related to study drug (PCC and plasma) related complications (volume overload, thrombotic complications) From last intervention/infusion until 30 days post heart transplant or until discharge
Primary Amount of Chest Tube Drainage Primary outcome: Amount of chest tube output in the first 24 hours From patient out of room time until 24 hours after
Secondary Postoperative INR INR value 30 Minutes post-treatment (after the last dose is completed)
Secondary Blood Product Use Total hemostatic blood product use including plasma, platelets, cryoprecipitate, and recombinant activated factor VII. In OR (from OR entry to OR out of room time); postoperatively (patient out of room time) to 24 hours after; from 24 hours after until 30 days post surgery or until discharge (whichever comes first)
Secondary Red Blood Cell Use Red Blood Cell Use Intraoperatively and Postoperatively Intraoperatively(from start of first intervention until start of second intervention;after 2nd intervention(post-bypass)until patient out of room time) & Postoperatively(from patient out of room time until 24 hours after;24 hours after until 30 days)
Secondary Need for circulatory support Percentage of patients who needed circulatory support (ECMO or VAD) 30 days post-operative or until discharge (whichever comes first)
Secondary Mechanical Ventilation Percentage of patients who needed mechanical ventilation for more than 72 hours 30 days post-operative or until discharge (whichever comes first)
Secondary Tracheostomy Percentage of patients who needed a tracheostomy 30 days post-operative or until discharge (whichever comes first)
Secondary Renal Failure Percentage of patients who experience renal failure requiring dialysis 30 days post-operative or until discharge (whichever comes first)
Secondary Sepsis Percentage of patients who experienced sepsis infection morbidity consisted of sepsis syndrome, septic shock, or mediastinitis. In addition, the diagnosis of sepsis included organisms isolated from the cultures along with elevated temperature and white blood cell counts. 30 days post-operative or until discharge (whichever comes first)
Secondary Death Percentage of patients who died 30 days post-operative or until discharge (whichever comes first)
Secondary Stroke or postoperative neurological dysfunction Percentage of patients who experienced a stroke or postoperative neurological dysfunction (seizures, delirium, unconsciousness, encephalopathy) 30 days post-operative or until discharge (whichever comes first)
Secondary Gastrointestinal complication requiring bowel resection Percentage of patients who experienced gastrointestinal complications requiring bowel resection 30 days post-operative or until discharge (whichever comes first)
Secondary Peripheral vascular complication Percentage of patients who experience peripheral vascular complications requiring surgery (thrombectomy, bypass, and amputations) 30 days post-operative or until discharge (whichever comes first)
Secondary Deep Vein Thrombosis and Pulmonary Thromboembolism Percentage of patients who develop a deep vein thrombosis and/ or pulmonary thromboembolism 30 days post-operative or until discharge (whichever comes first)
Secondary Plasma Coagulation Factor levels Plasma coagulator factor levels will be analyzed via blood laboratory tests At baseline, post-bypass/pre-protamine, 30 minutes post-protamine, 12-24 hours post treatment
Secondary Thrombin Generation Assay Thrombin Generation assay will be analyzed via blood laboratory tests At baseline, post-bypass/pre-protamine, 30 minutes post-protamine, 12-24 hours post treatment
Secondary Surgical Re-exploration Surgical Re-Exploration that is related to heart transplant surgery 30 days post-operative or until discharge (whichever comes first)
See also
  Status Clinical Trial Phase
Completed NCT03727646 - Nicotinamide Riboside in LVAD Recipients Early Phase 1
Withdrawn NCT03519477 - Comprehensive Medication Monitoring on Heart Failure Patient Outcomes N/A
Recruiting NCT05596760 - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers N/A
Recruiting NCT05227872 - PVF in Decongestion of Heart Failure
Recruiting NCT05543720 - Evaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study N/A
Completed NCT04572425 - Virtual Reality for Pain Management in Advanced Heart Failure N/A
Recruiting NCT03202329 - Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Recruiting NCT02672618 - Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology N/A
Recruiting NCT04179643 - NAN-101 in Patients With Class III Heart Failure Phase 1
Completed NCT04129658 - Heart Failure in Southern Sweden
Not yet recruiting NCT05591443 - Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT04628325 - Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) Phase 3
Completed NCT03187470 - Left Ventricular Dyssynchrony in Multipole Pacing N/A
Completed NCT03385837 - Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients
Completed NCT04281849 - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program N/A
Not yet recruiting NCT04403659 - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study N/A
Terminated NCT04142788 - RELieving Increasing oEdema Due to Heart Failure Phase 4
Active, not recruiting NCT04283994 - Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2) N/A